Form 4: Revolution Medicines CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Mark A. Goldsmith, the CEO of Revolution Medicines, executed stock options and sold shares of common stock.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on December 1, 2023.
- On November 1, 2024, Goldsmith exercised options to acquire 9,100 shares at $4.09 per share and sold 9,100 shares at a weighted average price of $55.0235.
- Additionally on November 1, 2024, Goldsmith sold 5,000 shares at a weighted average price of $55.0268 and another 5,000 shares at a weighted average price of $55.0209.
- On November 4, 2024, Goldsmith exercised options to acquire 50,900 shares at $4.09 per share and sold 50,900 shares at a weighted average price of $55.5564.
- Also on November 4, 2024, Goldsmith exercised options to acquire 36,600 shares at $0.49 per share.
- Following these transactions, Goldsmith directly owns 336,770 shares of common stock and indirectly owns 465,604 shares through a trust.
- He also holds options to purchase 243,075 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing plan. There's no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a standard part of executive compensation and portfolio management.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units.
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Vertex Pharmaceuticals, to manage their stock holdings and avoid potential insider trading concerns.
- The reported weighted average sale prices are within a normal range for stock transactions of this type.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 2011-12-15 | Date of the Goldsmith Children's 2011 Irrevocable Education Trust |
| 2020-12-01 | Exercisable date for stock options |
| 2023-03-13 | Exercisable date for stock options |
| 2023-12-01 | Date of adoption of 10b5-1 trading plan |
| 2024-11-01 | Date of stock option exercise and share sales |
| 2024-11-04 | Date of stock option exercise and share sales |
| 2024-11-05 | Date of signature |
| 2027-03-20 | Expiration date for stock options |
| 2029-03-12 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.